US 11,701,387 B2
Chimeric antigen receptor specific for BDCA2 antigen
Rafijul Bari, Gaithersburg, MD (US); Markus Granzin, Germering (DE); Wing Leung, Boston, MA (US); Andrzej Dzionek, Overath (DE); and Martin Meyer, Kürten (DE)
Assigned to Miltenyi Biotec B.V. & Co. KG
Appl. No. 16/959,330
Filed by Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach (DE)
PCT Filed Jan. 4, 2019, PCT No. PCT/EP2019/050123
§ 371(c)(1), (2) Date Jun. 30, 2020,
PCT Pub. No. WO2019/134950, PCT Pub. Date Jul. 11, 2019.
Claims priority of provisional application 62/613,632, filed on Jan. 4, 2018.
Prior Publication US 2020/0353003 A1, Nov. 12, 2020
Int. Cl. C07K 16/46 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/2851 (2013.01); C07K 2317/73 (2013.01)] 7 Claims
OG exemplary drawing
 
5. A composition comprising:
a) an immune cell expressing a CAR comprising:
i) an antigen binding domain specific for a tag of a tagged polypeptide, wherein said tagged polypeptide is an antibody or antigen binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2,
ii) a transmembrane domain,
iii) an intracellular signaling domain, and
wherein said antigen binding domain specifically binds a tag of a tagged polypeptide, wherein said polypeptide binds specifically to the antigen BDCA2 expressed on the surface of a target cell, wherein said target cell is a cancer cell expressing BDCA2, and
b) said tagged polypeptide.